Pesquisar
Takeda Pharmaceutical Co Ltd
TAKAdicionar à lista de desejos
18.260USD
+0.150+0.83%
Fechamento 09-11 16:00（ET）
57.74BValor de mercado
47.63P/L TTM
Após o expediente 19:00 (ET)18.260USD-0.015-0.08%
Após o expediente 19:00 (ET)Mais detalhes de Takeda Pharmaceutical Co Ltd Empresa
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
Takeda Pharmaceutical Co Ltd Perfil
Código da empresaTAK
Nome da EmpresaTakeda Pharmaceutical Co Ltd
Data de listagemJun 21, 2085
CEOWeber (Christophe)
Número de funcionários47455
Tipo de títulosDepository Receipt
Fim do ano fiscalJun 21
Endereço4F
CidadeCHUO-KU
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísJapan
Código postal103-8668
Telefone81332782111
Sitehttps://www.takeda.com/
Código da empresaTAK
Data de listagemJun 21, 2085
CEOWeber (Christophe)
Executivos da empresa Takeda Pharmaceutical Co Ltd
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Steven H. (Steve) Gillis, Ph.D.
Dr. Steven H. (Steve) Gillis, Ph.D.
Independent Director
Independent Director
15.86K
--
Ms. Kimberly A. Reed
Ms. Kimberly A. Reed
Independent Director
Independent Director
8.97K
--
Mr. Michel Orsinger
Mr. Michel Orsinger
Independent Director
Independent Director
7.60K
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
7.60K
--
Mr. Jean-Luc Butel
Mr. Jean-Luc Butel
Independent Director
Independent Director
7.60K
--
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
7.60K
--
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Dr. Andrew S. Plump, Ph.D.
Dr. Andrew S. Plump, Ph.D.
President of Research & Development, Director
President of Research & Development, Director
--
--
Mr. Tokumasa Takeda
Mr. Tokumasa Takeda
Global Finance Chief Accounting Officer & Corporate Controller
Global Finance Chief Accounting Officer & Corporate Controller
--
--
Mr. Yoshiaki Fujimori
Mr. Yoshiaki Fujimori
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Steven H. (Steve) Gillis, Ph.D.
Dr. Steven H. (Steve) Gillis, Ph.D.
Independent Director
Independent Director
15.86K
--
Ms. Kimberly A. Reed
Ms. Kimberly A. Reed
Independent Director
Independent Director
8.97K
--
Mr. Michel Orsinger
Mr. Michel Orsinger
Independent Director
Independent Director
7.60K
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
7.60K
--
Mr. Jean-Luc Butel
Mr. Jean-Luc Butel
Independent Director
Independent Director
7.60K
--
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
7.60K
--
Perguntas frequentes
Quem são os cinco principais acionistas de Takeda Pharmaceutical Co Ltd?
Os cinco principais acionistas de Takeda Pharmaceutical Co Ltd são: Dr. Steven H. (Steve) Gillis, Ph.D.
Quantas instituições possuem ações da Takeda Pharmaceutical Co Ltd (TAK)?
Em 2026Q1, 637 instituições possuíam ações da Takeda Pharmaceutical Co Ltd, com valor de mercado aproximado de 85.31M, representando 2.70% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -8142483.00.
Qual é a maior fonte de receita da Takeda Pharmaceutical Co Ltd?
Em 2026Q1, o segmento de negócios Gastrointestinal diseases gerou a maior receita para Takeda Pharmaceutical Co Ltd, totalizando 386.10B e representando 31.65% da receita total.